Study:
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck
Rationale:
Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Radiation therapy uses high-energy x-rays to kill tumor cells. Vandetanib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet
known whether giving chemotherapy together with radiation therapy is more effective with or
without vandetanib in treating patients with head and neck cancer.
Purpose:
This randomized phase II trial is studying giving chemotherapy together with
radiation therapy to see how well it works compared with giving chemotherapy and radiation
therapy together with vandetanib in treating patients with high-risk stage III or stage IV
head and neck cancer.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Head and Neck Cancer |
Drug: cisplatin
Drug: vandetanib
Radiation: radiation therapy |
Phase 2 |
Verified by
Radiation Therapy Oncology Group
March, 2013
Sponsored by: Radiation Therapy Oncology Group
Information provided by: Radiation Therapy Oncology Group
ClinicalTrials.gov identifier: NCT00720083
Study Type: Interventional
Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
David Raben, MD., Principal Investigator
John A. Ridge, MD, PhD., Study Chair
Stuart J. Wong, MD., Study Chair